The Star Ledger (“the voice of New Jersey”) has an ESCR story out, byline Kitta MacPherson, which is, as usual, biased in the direction of promoting ESCR. A study has been published in Nature reporting that human embryonic stem cells in mice effectively treated Sandhoff disease, a malady similar to Tay Sachs and other such neurological disorders. Much more is made of the story than is warranted, as I will explain below. However, I think the bias comes from ignorance rather than the reporter’s intent. A general staff reporter will naturally rely on the scientists for the facts—which in these highly politicized days will not always result in accurate reporting.
MacPherson got the usual spin. Check this out from the story: “Everybody is always saying to us, ‘Well, you guys studying the human embryonic stem cells, you haven’t benefited anyone yet,’” said Evan Snyder, a neuroscientist who has published breakthrough papers on both embryonic and adult stem cells. “Well, this is it.” Except, it isn’t. The study was done in rodents, not people. Surely, a neuroscientist (and a staff journalist, for that matter), knows that a mouse made better is not the same thing as a human made better. Indeed, what works in animal models does not always work in humans.
But note this part of the story. The scientists used both adult and embryonic stem cells in their experiments, with interesting results: The international team, headed by Snyder, a physician-scientist at the Burnham Institute in California, also compared the effectiveness of embryonic stem cells versus the “adult” variety and found them to be equally effective. In other words, in mice adult stem cells were just as therapeutic as embryonic! That should have been the headline and the story’s emphasis. Moreover, if this is so, why use ESCs in human trials, as these scientists want to do, given their propensity to cause tumors and their ethical contentiousness?
Chalk up another hyped story of a purported embryonic stem cell success that is less then advertised, and which actually boosts the argument in favor of adult stem cell research.
Dear Reader,
Can I be direct with you?
War abroad. Socialists on the rise. AI upending human life. Endless uproar online. The modern attention economy doesn’t want readers — it wants users enslaved to the tyranny of the present.
First Things is the antidote: literary excellence, timeless truths, and a fixed point of reference in a culture that has lost its bearings.
But we can’t do it without readers like you.
Our goal: Raise $150,000 by November 1 to sustain First Things in the year ahead.
Your gift anchors readers in the permanent things.
Make your Fall Campaign gift now using the button below.
If you have any questions or would like more information, please contact Giovanni Del Piero, Director of the Editor’s Circle, at gdelpiero@firstthings.com or 212-627-1985.
YOU MIGHT ALSO LIKE
The Church in the Age of Therapy
In 1966, Philip Rieff wrote in The Triumph of the Therapeutic that “Religious man was born to…
Canada’s Deadliest Blind Spot
On September 20, the Daily Mail ran a story with the provocative headline, “Our 83-year-old Christian grandmother…
The Faithful Joy of Dolly Parton and Fulton Sheen
Dolly Parton and Fulton Sheen seem to have had little in common. She favored rhinestones; he wore…
